PortalPublikationenEntwicklungen in der Therapie des fortgeschrittenen Ovarialk...

Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III

Standard

Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III. / Kuhn, W; Jänicke, F; Pache, L; Hölscher, M; Schattenmann, G; Schmalfeldt, B; Anderl, H; Schüle, G; Dettmar, P; Siewert, J R.

in: GEBURTSH FRAUENHEILK, Jahrgang 53, Nr. 5, 05.1993, S. 293-302.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kuhn, W, Jänicke, F, Pache, L, Hölscher, M, Schattenmann, G, Schmalfeldt, B, Anderl, H, Schüle, G, Dettmar, P & Siewert, JR 1993, 'Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III', GEBURTSH FRAUENHEILK, Jg. 53, Nr. 5, S. 293-302. https://doi.org/10.1055/s-2007-1022886

APA

Kuhn, W., Jänicke, F., Pache, L., Hölscher, M., Schattenmann, G., Schmalfeldt, B., Anderl, H., Schüle, G., Dettmar, P., & Siewert, J. R. (1993). Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III. GEBURTSH FRAUENHEILK, 53(5), 293-302. https://doi.org/10.1055/s-2007-1022886

Vancouver

Kuhn W, Jänicke F, Pache L, Hölscher M, Schattenmann G, Schmalfeldt B et al. Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III. GEBURTSH FRAUENHEILK. 1993 Mai;53(5):293-302. https://doi.org/10.1055/s-2007-1022886

Bibtex

@article{301cd2b65ac94652a31d4d2ba06177d4,
title = "Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III",
abstract = "From 1982 to 1992 103 patients with ovarian cancer stage FIGO III have been treated. In 38% of the patients there was no residual tumour postoperatively, in 40.8% the residual tumour was smaller than 2 cm. In 51.5% bowel resections were necessary, a stoma was unavoidable in just one case. A lymphadenectomy (pelvic, paraaortic or combined) was done in 46.6% of the patients. Postoperatively, 54.4% of the patients received a platinum-based chemotherapy, in the other patients other kinds of chemotherapy were applied. A radiation of the whole abdomen was done only in 3.9%. A median survival time for more than 60 months could be achieved in tumour-free patients due to the increased radical operations in combination with the platinum based chemotherapy. The lymphadenectomy seems to prolong the survival time of the patients. The positive nodal status is definitely unfavourable for the prognosis. By this therapeutic approach, an increased survival time with a good life quality can be achieved.",
keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Chemotherapy, Adjuvant, Cisplatin, Combined Modality Therapy, Cyclophosphamide, Female, Follow-Up Studies, Humans, Lymph Node Excision, Male, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Ovariectomy, Radiotherapy Dosage, Survival Rate",
author = "W Kuhn and F J{\"a}nicke and L Pache and M H{\"o}lscher and G Schattenmann and B Schmalfeldt and H Anderl and G Sch{\"u}le and P Dettmar and Siewert, {J R}",
year = "1993",
month = may,
doi = "10.1055/s-2007-1022886",
language = "Deutsch",
volume = "53",
pages = "293--302",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "5",

}

RIS

TY - JOUR

T1 - Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III

AU - Kuhn, W

AU - Jänicke, F

AU - Pache, L

AU - Hölscher, M

AU - Schattenmann, G

AU - Schmalfeldt, B

AU - Anderl, H

AU - Schüle, G

AU - Dettmar, P

AU - Siewert, J R

PY - 1993/5

Y1 - 1993/5

N2 - From 1982 to 1992 103 patients with ovarian cancer stage FIGO III have been treated. In 38% of the patients there was no residual tumour postoperatively, in 40.8% the residual tumour was smaller than 2 cm. In 51.5% bowel resections were necessary, a stoma was unavoidable in just one case. A lymphadenectomy (pelvic, paraaortic or combined) was done in 46.6% of the patients. Postoperatively, 54.4% of the patients received a platinum-based chemotherapy, in the other patients other kinds of chemotherapy were applied. A radiation of the whole abdomen was done only in 3.9%. A median survival time for more than 60 months could be achieved in tumour-free patients due to the increased radical operations in combination with the platinum based chemotherapy. The lymphadenectomy seems to prolong the survival time of the patients. The positive nodal status is definitely unfavourable for the prognosis. By this therapeutic approach, an increased survival time with a good life quality can be achieved.

AB - From 1982 to 1992 103 patients with ovarian cancer stage FIGO III have been treated. In 38% of the patients there was no residual tumour postoperatively, in 40.8% the residual tumour was smaller than 2 cm. In 51.5% bowel resections were necessary, a stoma was unavoidable in just one case. A lymphadenectomy (pelvic, paraaortic or combined) was done in 46.6% of the patients. Postoperatively, 54.4% of the patients received a platinum-based chemotherapy, in the other patients other kinds of chemotherapy were applied. A radiation of the whole abdomen was done only in 3.9%. A median survival time for more than 60 months could be achieved in tumour-free patients due to the increased radical operations in combination with the platinum based chemotherapy. The lymphadenectomy seems to prolong the survival time of the patients. The positive nodal status is definitely unfavourable for the prognosis. By this therapeutic approach, an increased survival time with a good life quality can be achieved.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carboplatin

KW - Chemotherapy, Adjuvant

KW - Cisplatin

KW - Combined Modality Therapy

KW - Cyclophosphamide

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Lymph Node Excision

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Ovarian Neoplasms

KW - Ovariectomy

KW - Radiotherapy Dosage

KW - Survival Rate

U2 - 10.1055/s-2007-1022886

DO - 10.1055/s-2007-1022886

M3 - SCORING: Zeitschriftenaufsatz

C2 - 8514099

VL - 53

SP - 293

EP - 302

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 5

ER -